Literature DB >> 29269393

Structural basis for the regulation of β-glucuronidase expression by human gut Enterobacteriaceae.

Michael S Little1, Samuel J Pellock1, William G Walton1, Ashutosh Tripathy2, Matthew R Redinbo3,2,4,5.   

Abstract

The gut microbiota harbor diverse β-glucuronidase (GUS) enzymes that liberate glucuronic acid (GlcA) sugars from small-molecule conjugates and complex carbohydrates. However, only the Enterobacteriaceae family of human gut-associated Proteobacteria maintain a GUS operon under the transcriptional control of a glucuronide repressor, GusR. Despite its potential importance in Escherichia, Salmonella, Klebsiella, Shigella, and Yersinia opportunistic pathogens, the structure of GusR has not been examined. Here, we explore the molecular basis for GusR-mediated regulation of GUS expression in response to small-molecule glucuronides. Presented are 2.1-Å-resolution crystal structures of GusRs from Escherichia coli and Salmonella enterica in complexes with a glucuronide ligand. The GusR-specific DNA operator site in the regulatory region of the E. coli GUS operon is identified, and structure-guided GusR mutants pinpoint the residues essential for DNA binding and glucuronide recognition. Interestingly, the endobiotic estradiol-17-glucuronide and the xenobiotic indomethacin-acyl-glucuronide are found to exhibit markedly differential binding to these GusR orthologs. Using structure-guided mutations, we are able to transfer E. coli GusR's preferential DNA and glucuronide binding affinity to S. enterica GusR. Structures of putative GusR orthologs from GUS-encoding Firmicutes species also reveal functionally unique features of the Enterobacteriaceae GusRs. Finally, dominant-negative GusR variants are validated in cell-based studies. These data provide a molecular framework toward understanding the control of glucuronide utilization by opportunistic pathogens in the human gut.

Entities:  

Keywords:  biochemistry; gut microbiota; molecular biology; structural biology; transcriptional regulation

Mesh:

Substances:

Year:  2017        PMID: 29269393      PMCID: PMC5777068          DOI: 10.1073/pnas.1716241115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  62 in total

Review 1.  UDP-glucuronosyltransferases: a family of detoxifying enzymes.

Authors:  T R Tephly; B Burchell
Journal:  Trends Pharmacol Sci       Date:  1990-07       Impact factor: 14.819

2.  The gusBC genes of Escherichia coli encode a glucuronide transport system.

Authors:  Wei-Jun Liang; Kate J Wilson; Hao Xie; Jan Knol; Shun'ichi Suzuki; Nicholas G Rutherford; Peter J F Henderson; Richard A Jefferson
Journal:  J Bacteriol       Date:  2005-04       Impact factor: 3.490

3.  Studies on the substrate specificity of human intestinal UDP- lucuronosyltransferases 1A8 and 1A10.

Authors:  Z Cheng; A Radominska-Pandya; T R Tephly
Journal:  Drug Metab Dispos       Date:  1999-10       Impact factor: 3.922

4.  Regulation of beta-glucuronidase synthesis in Escherichia coli K-12: pleiotropic constitutive mutations affecting uxu and uidA expression.

Authors:  M Novel; G Novel
Journal:  J Bacteriol       Date:  1976-07       Impact factor: 3.490

Review 5.  Glucuronides in the gut: Sugar-driven symbioses between microbe and host.

Authors:  Samuel J Pellock; Matthew R Redinbo
Journal:  J Biol Chem       Date:  2017-04-07       Impact factor: 5.157

6.  Commensal bacteria influence Escherichia coli O157:H7 persistence and Shiga toxin production in the mouse intestine.

Authors:  Shantini D Gamage; Angela K Patton; Jane E Strasser; Claudia L Chalk; Alison A Weiss
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

7.  An Atlas of β-Glucuronidases in the Human Intestinal Microbiome.

Authors:  Rebecca M Pollet; Emma H D'Agostino; William G Walton; Yongmei Xu; Michael S Little; Kristen A Biernat; Samuel J Pellock; Loraine M Patterson; Benjamin C Creekmore; Hanna N Isenberg; Rohini R Bahethi; Aadra P Bhatt; Jian Liu; Raad Z Gharaibeh; Matthew R Redinbo
Journal:  Structure       Date:  2017-06-01       Impact factor: 5.006

8.  Polysaccharide utilization loci and nutritional specialization in a dominant group of butyrate-producing human colonic Firmicutes.

Authors:  Paul O Sheridan; Jennifer C Martin; Trevor D Lawley; Hilary P Browne; Hugh M B Harris; Annick Bernalier-Donadille; Sylvia H Duncan; Paul W O'Toole; Karen P Scott; Harry J Flint
Journal:  Microb Genom       Date:  2016-02-09

9.  Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity.

Authors:  Bret D Wallace; Adam B Roberts; Rebecca M Pollet; James D Ingle; Kristen A Biernat; Samuel J Pellock; Madhu Kumar Venkatesh; Leah Guthrie; Sara K O'Neal; Sara J Robinson; Makani Dollinger; Esteban Figueroa; Sarah R McShane; Rachel D Cohen; Jian Jin; Stephen V Frye; William C Zamboni; Charles Pepe-Ranney; Sridhar Mani; Libusha Kelly; Matthew R Redinbo
Journal:  Chem Biol       Date:  2015-09-10

10.  Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study.

Authors:  Roberto Flores; Jianxin Shi; Barbara Fuhrman; Xia Xu; Timothy D Veenstra; Mitchell H Gail; Pawel Gajer; Jacques Ravel; James J Goedert
Journal:  J Transl Med       Date:  2012-12-21       Impact factor: 5.531

View more
  16 in total

1.  Pharmacological Activation of PXR and CAR Downregulates Distinct Bile Acid-Metabolizing Intestinal Bacteria and Alters Bile Acid Homeostasis.

Authors:  Joseph L Dempsey; Dongfang Wang; Gunseli Siginir; Qiang Fei; Daniel Raftery; Haiwei Gu; Julia Yue Cui
Journal:  Toxicol Sci       Date:  2019-03-01       Impact factor: 4.849

Review 2.  Allergic Inflammation: Effect of Propolis and Its Flavonoids.

Authors:  Nada Oršolić
Journal:  Molecules       Date:  2022-10-08       Impact factor: 4.927

3.  Decreased Tissue Omega-6/Omega-3 Fatty Acid Ratio Prevents Chemotherapy-Induced Gastrointestinal Toxicity Associated with Alterations of Gut Microbiome.

Authors:  Kanakaraju Kaliannan; Shane O Donnell; Kiera Murphy; Catherine Stanton; Chao Kang; Bin Wang; Xiang-Yong Li; Atul K Bhan; Jing X Kang
Journal:  Int J Mol Sci       Date:  2022-05-10       Impact factor: 6.208

4.  Gut microbial β-glucuronidases reactivate estrogens as components of the estrobolome that reactivate estrogens.

Authors:  Samantha M Ervin; Hao Li; Lauren Lim; Lee R Roberts; Xue Liang; Sridhar Mani; Matthew R Redinbo
Journal:  J Biol Chem       Date:  2019-10-21       Impact factor: 5.486

5.  Cinnamic acid derivatives: inhibitory activity against Escherichia coli β-glucuronidase and structure-activity relationships.

Authors:  Xing-Nuo Li; Lu-Xia Hua; Tao-Shun Zhou; Ke-Bo Wang; Yuan-Yuan Wu; Mahmoud Emam; Xiao-Ze Bao; Jun Chen; Bin Wei
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

6.  Transcription factor allosteric regulation through substrate coordination to zinc.

Authors:  Beatriz C Almeida; Jennifer A Kaczmarek; Pedro R Figueiredo; Kristala L J Prather; Alexandra T P Carvalho
Journal:  NAR Genom Bioinform       Date:  2021-05-03

7.  Predicting drug-metagenome interactions: Variation in the microbial β-glucuronidase level in the human gut metagenomes.

Authors:  Moamen M Elmassry; Sunghwan Kim; Ben Busby
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

8.  Targeting Regorafenib-Induced Toxicity through Inhibition of Gut Microbial β-Glucuronidases.

Authors:  Samantha M Ervin; Ronan P Hanley; Lauren Lim; William G Walton; Kenneth H Pearce; Aadra P Bhatt; Lindsey I James; Matthew R Redinbo
Journal:  ACS Chem Biol       Date:  2019-11-12       Impact factor: 4.634

Review 9.  Harnessing the Power of Microbiome Assessment Tools as Part of Neuroprotective Nutrition and Lifestyle Medicine Interventions.

Authors:  Miguel Toribio-Mateas
Journal:  Microorganisms       Date:  2018-04-25

10.  Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy.

Authors:  Aadra P Bhatt; Samuel J Pellock; Kristen A Biernat; William G Walton; Bret D Wallace; Benjamin C Creekmore; Marine M Letertre; Jonathan R Swann; Ian D Wilson; Jose R Roques; David B Darr; Sean T Bailey; Stephanie A Montgomery; Jeffrey M Roach; M Andrea Azcarate-Peril; R Balfour Sartor; Raad Z Gharaibeh; Scott J Bultman; Matthew R Redinbo
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.